Navigation Links
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Date:10/5/2007

BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the presentation of positive safety and efficacy data from its innovative Phase 1 repeat-dose clinical trial of its investigational drug candidate SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride transfer protein (MTP) inhibitor being developed for the treatment of dyslipidemia (abnormal levels of lipids in the bloodstream). The data indicated not only that repeat- dosing at all dose levels of SLx-4090 was well tolerated, with no serious adverse events reported, but also that SLx-4090 significantly decreased plasma levels of both triglyceride and LDL-cholesterol compared to placebo. These data extend earlier findings previously reported from a single-dose study relating to the safety, tolerability and pharmacokinetic and pharmacodynamic profiles of SLx-4090. Results were presented at the 16th International Symposium on Drugs Affecting Lipid Metabolism being held October 4-7 in New York, NY.

"It is exciting that this novel compound continued to perform so well in this first repeat-dose study," said Dr. William Prince, Chief Development Officer of Surface Logix. "Consistent with our preclinical and Phase 1 single-dose results, no drug was detected in the plasma at doses up to 200 mg given three times daily for two weeks. This is particularly notable, as all other known MTP inhibitors have been shown to enter the systemic circulation and negatively impact standard measures of liver function. SLx-4090 was extremely well tolerated and adverse events were similar to those seen with placebo."

"Based on the results of this study, we have advanced SLx-4090 into a Phase 2a study, which will be completed shortly, and initial results are confirming the profile seen in both Phase 1 studies," said Jim Mahoney, President and Chief Executive Officer of Surface Logix. "We are also planning to start a Phase 2b study in patients with dyslipidemia in the middle of 2008. Based on
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014  Neuraltus Pharmaceuticals, ... Company,s Phase 2 clinical program of NP001 for the ... Gehrig,s disease) are being highlighted today in an ... ALS Research Group , being held in ... a  post hoc  analysis, administration of a high dose ...
(Date:9/17/2014)... 2014  Fortune Oil and Gas, Inc. (OTCPink:FOGC), today ... Manzo Pharmaceuticals, Inc. with the symbol (OTCPink : FOGCD). ... 17, 2014. Also taking effect today is a ten ... a pivotal event in the company,s progress according to ... could not proceed with the plan and still have ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... 17, 2014 The International Journal of Surgery ... its archive of previously published content: after 24 months published ... aim of the IJS is to improve surgical ... making these articles available to all will improve efforts to ... IJS said, "The journal has always been a great ...
(Date:9/17/2014)... In ongoing coverage of formulary exclusion ... (DBN) continues to find criticism surrounding the tactic. ... issue , CVS Caremark Corp. and Express Scripts ... cut more drugs than ever, but industry consultants ... likely to achieve. Despite finding the strategy problematic, ...
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... Mission Viejo, CA (PRWEB) September 17, 2014 ... meetings and events, announced today it has released ... engagement at large meetings and corporate events. The ... up, enhance presentation and document management capabilities and ... speaker and participants. , Lintelus Meeting 3.1 ...
(Date:9/17/2014)... 2014 Market Research Report on ... in-depth research report on the China DEHP Plasticizer ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 3
... 2012) According to the results of a new ... Journal of the American College of Surgeons , ... disease and were not meaningfully involved in treatment discussions ... As a result, the study,s investigators determined that there ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... January/February issue of Annals takes an up-close look ... a single individual, a phenomenon that is growing at an ... is estimated by the year 2020, 25 percent of the ... costs for managing these conditions will reach $1.07 trillion. In ...
... injury (AKI) has severe consequences, with a 25 to 80 ... to diagnose AKI using a urine test, enabling emergency departments ... the hospital. The study will be published online on January ... of Cardiology. Physicians typically measure a patient,s creatinine ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 9 ... heartbreaking grief, suggests new research that finds losing a loved ... a day of a significant other,s death, heart attack risk ... at data on nearly 2,000 heart attack patients. And within ...
... risk of suffering a heart attack increases by approximately 21 ... one, according to a study lead by researchers at Beth ... 9 online in the journal Circulation found the ... the first week after the death of a loved one, ...
Cached Medicine News:Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 2Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:January/February 2012 Annals of Family Medicine 2Health News:January/February 2012 Annals of Family Medicine 3Health News:January/February 2012 Annals of Family Medicine 4Health News:January/February 2012 Annals of Family Medicine 5Health News:January/February 2012 Annals of Family Medicine 6Health News:January/February 2012 Annals of Family Medicine 7Health News:January/February 2012 Annals of Family Medicine 8Health News:January/February 2012 Annals of Family Medicine 9Health News:Biomarkers identify acute kidney injury in emergency patients 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Heart attack risk rises after loss of loved one 2
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... system for fast, accurate filling of 96 or ... controlled dispensing mechanism, ensures that no liquid can ... that come into contact with the liquid path ... unique compact design saves valuable bench space and ...
... Personal Pipettor is a cost-effective ... pipetting needs, from reagent additions ... more. Systems are available in ... using either fixed or disposable ...
... the newest addition to Thermos Multidrop family. ... of 1-50 l into 384- and 96-well ... a 384-well plate takes only 14 s. ... accuracy typically 10% at 2 l, which ...
Medicine Products: